Le Lézard

Communiqués de presse par sujet : Essais cliniques / Découvertes médicales

1 2 3 4 5 6 7 8 9 10 11 12 13 14

7 juin 2018

09:20
Medisafe, the leading medication management platform with almost four and a half million registered users, today released data showing that previously non-adherent HIV patients increase their prescription refills after they start using the company's...

09:00
CytRx Corporation , a biopharmaceutical research and development company specializing in oncology, today highlighted clinical data from partner NantCell's poster presentation on June 2, 2018 at the American Society of Clinical Oncology (ASCO) 2018...

09:00
DxTerity, a patient-centric genomics company developing at-home RNA monitoring blood tests for immune-mediated diseases, today announced that data from the LIFT (Lupus Interval Monitoring to Manage Disease Flare and Enable Treatment Optimization)...

08:30
TELA Bio®, Inc., a surgical reconstruction company leading the development and commercialization of OviTex® Reinforced BioScaffolds (RBSs) for soft tissue repair, today announced that early outcomes from the company's post-market BRAVO (BioScaffold...

08:00
Amplyx Pharmaceuticals, a company developing first-in-class products for life-threatening infections, today announced that Amplyx and its collaborators will be participating in and presenting at two scientific conferences in the upcoming weeks....

08:00
Lipocine Inc. , a specialty pharmaceutical company, today announced the dosing of the first subject in the ambulatory blood pressure ("ABPM") clinical study for TLANDOtm, the Company's oral testosterone product candidate for testosterone replacement...

02:00
4D pharma plc (AIM: DDDD) a annoncé aujourd'hui un accord avec une filiale de MSD (nom commercial de Merck & Co., Inc., Kenilworth, New Jersey, États-Unis) pour conduire un essai clinique afin d'évaluer l'association du KEYTRUDA® (pembrolizumab),...

02:00
4D pharma plc (AIM: DDDD) today announced an agreement with a subsidiary of MSD (tradename of Merck & Co., Inc., Kenilworth, N.J., USA) to conduct a clinical trial evaluating the combination of KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy marketed...

01:00
Late-breaking oral presentation on bimekizumab shows significant potential for treating ankylosing spondylitis (AS) Oral presentation on CIMZIA® (certolizumab pegol) pregnancy outcomes shows no increased risk of major congenital malformations...


6 juin 2018

16:05
Proteostasis Therapeutics, Inc. , a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today...

15:08
Sirnaomics, Inc. (www.sirnaomics.com), a leading biopharmaceutical company in development of RNAi therapeutics, announces today that it has closed Series C1 financing of US$25 Million (RMB?160 Million). This round of financing was led by Yuexiu New...

14:53
CardioNXT and AFTx, related privately-held medical device companies, jointly announced today that the Real-time electrogram Analysis for Drivers of Atrial fibRillation (RADAR) clinical trial has reached full enrollment with 65 treated patients....

10:08
The Antimicrobials Working Group (AWG) today announced that 13 of its member companies will present data from their clinical and research programs at the American Society for Microbiology's ASM Microbe 2018 meeting to be held June 7-11 in Atlanta,...

09:00
PENTAX Medical Company, a healthcare industry leader in diagnostic and therapeutic endoscopy, announced today the results about the C2 CryoBalloontm Ablation System's clinical efficacy, durability, and patient tolerability from various studies...

09:00
At the American Headache Society's (AHS) 60th Annual Scientific Meeting, leading researchers specializing in migraine, cluster headache and post-traumatic headache, will present groundbreaking data on innovative pharmacological and...

09:00
FUJIFILM Cellular Dynamics, Inc. (FCDI), a leading developer and manufacturer of human induced pluripotent stem cells (iPSCs) and differentiated tissue-specific iPSCs, announced today that it has entered into an exclusive patent license agreement...

09:00
Israeli biotechnology company Kadimastem announced that its scientific research has been published in the prestigious medical journal Stem Cell Research and Therapy. The link to the article is:...

08:59
Thermi®, an Almirall S.A. company, today announced that its ThermiVa® device has been shown to deliver significant improvements in common vaginal disorders and improve sexual satisfaction, according to a study published in the peer-reviewed journal...

08:30
SCYNEXIS, Inc. , a biotechnology company developing innovative therapies for difficult-to-treat and often life-threatening infections, today announced the publication of results from a Phase 1 study of SCY-078, assessing the risk for drug-drug...

08:00
Iterum Therapeutics plc , a clinical-stage pharmaceutical company developing anti-infectives against multi-drug resistant pathogens, will present four posters at the American Society of Microbiology MICROBE meeting in Atlanta from June 7 - 10, 2018....

08:00
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that topline results from the pivotal QuANTUM-R phase 3 study of single agent quizartinib will be presented for the first time at the 23rd Congress of the European Hematology...

07:00
Alkermes plc today announced it has received a $50 million payment from Biogen. This payment follows Biogen's review of preliminary gastrointestinal tolerability data from the ongoing clinical development program for BIIB098 (diroximel fumarate)....

02:53
On April 22, 2018, the 4th annual China-US Innovation Competition hosted by Entrepreneur Foundation (www.bsef.us) successfully took place in Questrom School of Business at Boston University. After the preliminary review, 8 finalists were selected...

00:00
Today Spyryx shared positive data for the first cohort of the SPX-101 Phase 2 clinical trial HOPE-1 (Hydration for Optimal Pulmonary Effectiveness), which showed that treatment with SPX-101 in patients with cystic fibrosis (CF) resulted in a...


5 juin 2018

17:56
More than 16 million people in the United States are affected by diabetes, a metabolic condition resulting in high blood sugar levels. A new research article published in the June 1, 2018 issue of the Journal of the American Academy of Orthopaedic...

17:01
Eisai Co., Ltd. (CEO: Haruo Naito, "Eisai") and Purdue Pharma L.P. (President and CEO: Craig Landau, "Purdue Pharma") today presented the results of two key Phase 1 clinical studies of their investigational sleep/wake regulation agent lemborexant at...

16:30
Therapix Biosciences Ltd. ("Therapix" or the "Company"), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced that on June 05, 2018, the first subject was enrolled for its Phase...

16:30
Researchers at Exact Sciences Corp. and Mayo Clinic announced significant progress toward developing a panel of novel, blood-based, DNA biomarkers that could accurately detect hepatocellular carcinoma (HCC), the most common cancer that originates in...

13:55
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Headquarters: Cambridge, Massachusetts, United States, CEO: Michel Vounatsos, "Biogen") announced today that elenbecestat was generally safe and well tolerated in a...

12:00
Takeda Canada has joined other industry and government partners by contributing financial support to CATALIS, an important and comprehensive program to promote investment in early clinical research in Quebec. The announcement is being made in advance...

12:00
Takeda Canada s'est jointe à d'autres partenaires de l'industrie et du gouvernement en apportant son soutien financier à CATALIS, un programme complet de grande importance qui fait la promotion de l'investissement dans la recherche clinique précoce...

11:16
L'Oncopole est fier d'annoncer, dans le cadre de son premier concours EMC2, un investissement de près de 12 M$ soutenant sept projets fédérateurs en oncologie au Québec. Cet investissement est possible grâce à une collaboration sans précédent avec...

11:15
The Oncopole is proud to announce, as part of its first EMC2 competition, an investment of close to $12M to support seven oncology projects in Quebec. This investment is made possible thanks to an unprecedented collaboration with leading funders,...

10:49
Kemwell Biopharma, a biologics contract development and manufacturing service provider, announced today that it has signed a contract to manufacture and supply drug substance using its state-of-the-art mammalian cell culture plant in India for Phase...

10:15
Eli Lilly and Company announced today new safety and efficacy data from a Phase 2 study evaluating mirikizumab in patients with moderate-to-severe ulcerative colitis (UC). The results showed that patients treated with mirikizumab achieved...

10:00
Polaris Group, a biopharmaceutical company focused on developing novel drugs for cancer, announced results from a phase 1 clinical study that features Polaris lead therapeutic candidate ADI-PEG 20 in combination with pemetrexed and cisplatin...

09:30
Today at Digestive Disease Week® (DDW), in Washington, D.C., Ferring Pharmaceuticals Inc. will present clinical trial data from 12:00-2:00 p.m. in Hall C of the Walter E. Washington Convention Center. In a poster session, Dr. Lawrence Hookey will...

09:01
miR Scientific, LLC formerly known as miR Diagnostics (miR or the Company), a precision molecular bioscience company, today announces the acceptance of two abstracts and a poster presentation by the American Society of Clinical Oncology (ASCO) at its...

09:00
Emboline, Inc., an emerging medical device company with a game-changing device for total embolic protection during transcatheter aortic valve replacement (TAVR) procedures, announced today the successful completion of its initial series of human...

08:30
Abstract #8018  The modelled data on overall survival of the statistical evaluation of the impact of crossover on the ADMYRE study were presented. Of the 84 patients treated in the comparator arm (dexamethasone as a single agent), 44%...

08:30
AbbVie , a research-based global biopharmaceutical company, today announced positive top-line results from SELECT-EARLY showing that both doses of upadacitinib monotherapy (15 mg and 30 mg) met the primary endpoints of ACR50a at week 12 and clinical...

08:30
Résumé numéro 8018   Les données modélisées sur la survie globale par l'évaluation statistique de l'impact de l'étude croisée (cross-over) ADMYRE ont été présentées.   Sur les 84 patients traités dans le groupe de comparaison (la...

08:30
Ampio Pharmaceuticals, Inc. today announced two peer-reviewed articles on the clinical application of Ampiontm are now available online. "Peer-reviewed journals are an important part of the scientific process, which...

08:14
A new study proves that enhanced terminal room disinfection with Tru-D SmartUVC leads to a decrease in risk of acquisition of targeted multidrug-resistant organisms such as C. diff and VRE for all patients, hospital-wide. The study, Effectiveness of...

08:02
Montmorency tart cherry juice may play a role in maintaining heart health, suggests a new study published in Food & Function. Researchers at the University of Delaware found that older adults who drank tart cherry juice made from U.S. grown...

08:00
The STATIN trial (RandomiSed conTrolled trial with prAvasTatin versus placebo for preventIoN of preeclampsia) is a European interventional trial, steered by the Fetal Medicine Foundation (FMF) and the Fundación para la Formación e Investigación...

08:00
ReShape Lifesciences Inc. , a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that the United States Patent and Trademark Office (USPTO) has granted a method and device patent to the Company...

08:00
Children with Complex Movement Disorders (CMD) see a "significant" improvement after treatment with medical cannabis, a new study using Tikun Olam's high-CBD, low -THC Avidekeltm strain confirms. The study, "Medical...

08:00
To improve the care of patients with acute or chronic pain, a consortium from academia, small and medium-sized enterprises (SMEs), pain societies, patient organizations and pharmaceutical industry launched the research project "IMI-PainCare -...

07:00
Results of a new analysis of real-world safety data presented at a major medical conference in Washington, D.C. show patients given the gut-selective Takeda biologic treatment ENTYVIO® (vedolizumab) had fewer serious infections and adverse events...

1 2 3 4 5 6 7 8 9 10 11 12 13 14